Literature DB >> 12519358

Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation.

F W Goldstein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12519358     DOI: 10.1046/j.1469-0691.2002.00492.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  15 in total

1.  A novel extended-spectrum TEM-type beta-lactamase, TEM-138, from Salmonella enterica serovar Infantis.

Authors:  Chedly Chouchani; Renaud Berlemont; Afef Masmoudi; Moreno Galleni; Jean-Marie Frere; Omrane Belhadj; Kamel Ben-Mahrez
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Cefepime dosing in the morbidly obese patient population.

Authors:  Barrie S Rich; Rebecca Keel; Vanessa P Ho; Harma Turbendian; Cheguevara I Afaneh; Gregory F Dakin; Alfons Pomp; David P Nicolau; Philip S Barie
Journal:  Obes Surg       Date:  2012-03       Impact factor: 4.129

3.  Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp.

Authors:  W Michael Dunne; Daniel J Hardin
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Quantifying the effect of in-hospital antimicrobial use on the development of colistin-resistant Acinetobacter baumannii strains: a time series analysis.

Authors:  Rania Kousovista; Christos Athanasiou; Konstantinos Liaskonis; Olga Ivopoulou; Vangelis D Karalis
Journal:  Eur J Hosp Pharm       Date:  2022-03

5.  Comparison of Ceftriaxone and Antipseudomonal β-Lactam Antibiotics Utilized for Potential AmpC β-Lactamase-Producing Organisms.

Authors:  David M Peters; Jessica B Winter; Christopher A Droege; Neil E Ernst; Siyun Liao
Journal:  Hosp Pharm       Date:  2020-06-04

6.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.

Authors:  Mitchell J Schwaber; Camilla S Graham; Bruce E Sands; Howard S Gold; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 8.  Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials.

Authors:  S J Edwards; M J Clarke; S Wordsworth; C E Emmas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-29       Impact factor: 3.267

Review 9.  Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.

Authors:  Mical Paul; Dafna Yahav; Assaf Bivas; Abigail Fraser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 10.  Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.

Authors:  Karen Bush
Journal:  Crit Care       Date:  2010-06-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.